New Zealand markets closed
  • NZX 50

    12,551.93
    +10.73 (+0.09%)
     
  • NZD/USD

    0.6951
    -0.0056 (-0.81%)
     
  • NZD/EUR

    0.5851
    -0.0025 (-0.43%)
     
  • ALL ORDS

    7,624.30
    +23.80 (+0.31%)
     
  • ASX 200

    7,368.90
    +9.90 (+0.13%)
     
  • OIL

    71.59
    +0.55 (+0.77%)
     
  • GOLD

    1,771.00
    -3.80 (-0.21%)
     
  • NASDAQ

    14,065.95
    -97.86 (-0.69%)
     
  • FTSE

    7,017.47
    -135.96 (-1.90%)
     
  • Dow Jones

    33,380.88
    -442.57 (-1.31%)
     
  • DAX

    15,448.04
    -279.63 (-1.78%)
     
  • Hang Seng

    28,801.27
    +242.68 (+0.85%)
     
  • NIKKEI 225

    28,964.08
    -54.25 (-0.19%)
     
  • NZD/JPY

    76.5400
    -0.6450 (-0.84%)
     

Malignant Mesothelioma - Competitive Landscape in 2021

·2-min read

Summary In malignant mesothelioma, cells expressing mesothelin is a major focus of drug developers. There are 178 drugs in the pipeline with 84% molecules present in early stage development.

New York, June 11, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Malignant Mesothelioma - Competitive Landscape in 2021" - https://www.reportlinker.com/p06094216/?utm_source=GNW


Big Pharma dominates R&D in this indication, with Bayer and Eli Lilly leading the way. The rise in treatment receiving population and increasing preference for branded tbiologic herapies will drive the market’s growth over the next six years, but delayed diagnosis and low surveillance rate are likely to limit market growth.

This reports provides a data-driven overview of the current and future competitive landscape in malignant mesothelioma therapeutics.

"Malignant Mesothelioma - Competitive Landscape in 2021" combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Scope
Components of the report include -
- Disease epidemiology
- Marketed drugs assessment
- Pipeline drugs assessment
- Clinical trials assessment
- Commercial assessment
- Social media overview
- Digital marketing overview

Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global malignant mesothelioma market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global malignant mesothelioma market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Read the full report: https://www.reportlinker.com/p06094216/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting